MRNA - Moderna, Inc.
| Previous Close | 14.16 |
| Open | 14.08 |
| Bid | 13.50 x 1800 |
| Ask | 14.68 x 2200 |
| Day's Range | 13.83 - 14.36 |
| 52 Week Range | 11.54 - 29.79 |
| Volume | 1,501,049 |
| Avg. Volume | 1,530,825 |
| Market Cap | 4.583B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.35 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.31 |
- Zacks
Moderna (MRNA) Jumps: Stock Rises 5.6%
Moderna (MRNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Schaeffer's Investment Research
FDA Nods Fuel Unusual Options Volume on NBRV, MRNA
Call options are running much hotter than usual today
- TheStreet.com
Moderna Stock Surges as FDA Fast Tracks Zika Vaccine
Moderna shares jumped as much as 8.5% on Tuesday, then pulled back, after the biotechnology company said the U.S. Food and Drug Administration granted fast-track designation for its investigational Zika vaccine. The Cambridge, Mass., drug developer said the vaccine, mRNA-1893, is being evaluated in a Phase I study to prevent Zika virus infection in healthy adults. "Protecting against Zika virus transmission, particularly in women during pregnancy, continues to be an area of high unmet need," Tal Zaks, a physician and the company's chief medical officer, said in a statement.
- Benzinga
The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 19) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Avid ...
- MarketWatch
Moderna stock pops after Zika vaccine gets FDA fast track
Shares in Moderna Inc. jumped 7% in extended trading Monday, after the company announced that the Food and Drug Administration had approved its potential vaccine for the Zika virus for a fast track to approval. Zika, a disease spread by mosquitoes, spread in 2016, and many companies are attempting to develop vaccines to the disease. Moderna's attempt at a vaccine is currently in a Phase 1 study, and is being especially targeted to avoiding transmission of the disease from a mother to an unborn child. "Protecting against Zika virus transmission, particularly in women during pregnancy, continues to be an area of high unmet need. Fast Track designation supports our belief in the clinical potential of mRNA-1893 and the importance of developing an effective vaccine that can be rapidly developed and deployed," Chief Medical Officer Tal Zaks said in Monday's announcement. Moderna went public late last year in the biggest initial public offering from a biotechnology company, raising more than $600 million at a valuation of more than $7 billion. Shares have struggled in recent months, closing Monday at $13.40, well short of the $23 price charged in the IPO but still enough for a $4.4 billion market cap.
- Business Wire
Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults. Fast Track is designed to facilitate the development and expedite the review of therapies and vaccines for serious conditions and fill an unmet medical need.
- American City Business Journals
WeWork joins underperforming Uber, Lyft, Nio as biggest pre-IPO cash guzzlers
All 10 companies on this list of the biggest pre-IPO cash guzzlers are either trading below their first day offering price or are out of business.
Motley FoolModerna, Inc. (MRNA) Q2 2019 Earnings Call Transcript
MRNA earnings call for the period ending June 30, 2019.
- Business Wire
Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results
Phase 2 Personalized Cancer Vaccine study initiated, with first patient consented
- InvestorPlace
7 Strong Buy Stocks the Street Loves
[Editor's note: "7 Strong Buy Stocks the Street Loves" was previously published in April 2019. It has since been updated to include the most relevant information available.]Which top stocks are Wall Street analysts the most bullish on? I mean stocks with a strong "buy" analyst consensus. These are the stocks that make the most compelling investing opportunities and are definitely worth keeping a close eye on.Using TipRanks powerful stock screener, I set out to pinpoint seven stocks that command the support of the Street. You can customize the screener settings to match your investment strategy. In this case, I selected filters for stocks of all market cap size with a "buy" consensus from analysts and best-performing analysts alike. These are the top analysts with the highest success rate and average return.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere I specifically select stocks with big upside potential from the current share price. This is based on the upside potential from the current share price to the average analyst price target. * The 10 Best Stocks to Invest in for August Now let's delve into these seven top stocks to buy now: Strong Buy Stocks: Exact Sciences (EXAS)Earlier this year, Exact Sciences Corporation (NASDAQ:EXAS) has just received five back-to-back buy ratings from the Street. These "buys" flooded in following stellar Q4 earnings results. EXAS delivered a solid Q4 revenue beat and raised its 2019 revenue guidance to $710 million-$730 million, above its prior $700 million estimate.Plus the future looks bright for sales of its Cologuard DNA test for colon cancer."EXAS is one of our top picks for 2019, and we reiterate our "buy" rating and our $100 PT," said five-star Canaccord Genuity analyst Mark Massaro. "Exact continues to execute at a high level and isn't afraid to make big investments to hit its ambitious goal of achieving $6 billion of revenue for Cologuard over time."That would give the company over 40% market share for its revolutionary screening product, first launched back in 2014.According to Massaro, even the new revenue guidance is beatable, writing "we see a path to upside to our raised estimates." A similar message comes from Baird's Catherine Ramsey. She writes: "We continue to see the potential for upside… and EXAS remains one of our top ideas."The average analyst price target right now stands at $128.33. Bear in mind shares have surged 87% year-to-date. Want to learn more about Exact Sciences? Get the free EXAS Stock Research Report. OpenText (OTEX)Canadian cloud computing stock Open Text Corp (NASDAQ:OTEX) develops and sells enterprise information management (EIM) software. Essentially, this helps organizations safely manage and share business information.Since the company's inception in 1991, OpenText has deployed around $6 billion capital on acquisitions. Using these acquisitions, OTEX can cement its position as a leader in the EIM space."Our strategy is total growth," said CEO Mark Barrenechea said, "where M&A will continue to be our largest growth driver, augmented with organic growth." So far this strategy appears to be paying off. * The 10 Best Stocks to Invest in for August "We believe OpenText is likely to continue to create shareholder value through its acquisition strategy," RBC analyst Paul Treiber said following the encouraging Q2 numbers,Analysts have a $46.75 average price target on the shares -- over 10% above the current share price. Get the OTEX Stock Research Report. Moderna (MRNA)Moderna (NASDAQ:MRNA) is a pioneer in a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. No less than eight analysts have published recent buy ratings on the stock.Earlier this year, the company reported positive results from an ongoing phase Ib trial. This is for mRNA-1653, an mRNA-based vaccine for the treatment of human metapneumovirus (HMPV) and parainfluenza virus (PIV3)."The interim phase I data announced today support our outlook for this experimental product and support advancing studies in the pediatric population" said Oppenheimer's Leah R Cann.The mRNA-1653 program is one of Moderna's 21 most current and importantly, one of its 13 focus programs.She points out that currently there are no approved vaccines to prevent hMPV or PIV3 infections, and estimates that worldwide mRNA-1653 sales could reach $1.44 billion by 2030. That's with a predicted launch date of 2024. Get the MRNA Stock Research Report. Nexstar Media (NXST)Following its completion of the Media General acquisition, Nexstar Media Group (NASDAQ:NXST) owns 171 television stations. As the largest TV station operator in the U.S. reaching nearly 39% of households, Nexstar Media Group is a stock worth watching.Analysts certainly seem to think so. Nexstar has received many buy calls in recent months from the Street. Most notably, Evercore ISI's David Joyce upgraded NXST from "hold" to "buy" back in December.Crucially, the company recently acquired many stations. It has agreed to a $6.4 billion deal to buy Tribune's ABC, CBS, FOX, and NBC stations. Tribune shareholders recently approved the deal. What's more, to help avoid any anti-trust issues, Nexstar has announced that it would sell 14 stations. * The 10 Best Stocks to Invest in for August "We assign Nexstar an Outperform rating and a $112 price target. We believe that the Tribune acquisition should create significant value for shareholders," top RBC Capital analyst Leo Kulp tells investors.He ramped up his price target from $96 to $112, adding, "We see limited risk around regulatory approvals…We expect the FCF yield to moderate as the company completes the milestones to closing the deal and de-levers post-closing." Get the NXST Stock Research Report. Boyd Gaming (BYD)Shares in Boyd Gaming Corp (NYSE:BYD) have jumped 34% in 2019 . That's partially thanks to a pretty exceptional Q4 earnings report for the Paradise, Nevada-based casino company."BYD's 4Q18 operating results were nothing short of sensational," said five-star Stifel Nicolaus analyst Steven Wieczynski. "BYD's strong 4Q18 results (were) an exclamation point on a strong 2018, with guidance above expectations serving as the cherry on top."With widespread growth throughout the business, BYD EBITDAR came in at $208.6mm, easily surpassing the estimated $197.1 million. Meanwhile 2019 EBITDAR guidance was established at a healthy $885 million-910 million, the midpoint of which was above Consensus forecasts ahead of the print ($888 million)."Post the strong 4Q18 results and with, we believe BYD is well positioned to continue to show healthy and steady same-store growth, while continuing to integrate its accretive acquisitions from the 2H18," said Deutsche Bank's Carlo Santarelli.That's with a "very compelling" current valuation to boot. With a " buy" analyst consensus, BYD boasts fa $35.60 average price target (25% upside potential). Get the BYD Stock Research Report. LivePerson (LPSN)As the name suggests, LivePerson (NASDAQ:LPSN) provides online real-time assistance and expert advice. The cloud-based chat company is near its all-time highs after its CEO in May said that it expects to end the year with an annual revenue run rate of around 20%. Shares are now up 73% year-to-date.Going forward, analysts are firmly bullish about LivePerson's outlook. Many analysts have published "buy" ratings on the stock this year, including (five-star Oppenheimer analyst Koji Ikeda. * The 10 Best Stocks to Invest in for August "We believe LivePerson is well positioned to take share in a large B2C messaging opportunity that is disrupting the contact center" writes Ikeda. "Organizations around the world are under pressure to rethink and retool legacy technologies with next-generation customer engagement applications, like LivePerson, to better engage, retain, and generate revenue from the end-consumer" the analyst explains.He believes that over time, good execution in quarterly results and improving business fundamentals should narrow the valuation gap between LPSN and the SaaS Industry average. That makes it a great strong buy stock. Get the LPSN Stock Research Report. Cubic Corp (CUB)Despite Brexit concerns and increasing volatility, growth remains par for the course for Irish defense contractor Cubic Corp (NYSE:CUB).The company has three key business divisions. For investors, it is the company's flagship Cubic Transportation Systems unit that is worth keeping an eye on. According to the company, this is the division responsible for "automated fare payment, traffic management and enforcement solutions."Indeed, transport systems revenue was up 24% year over year, according to CUB's Q1 earnings report. Consequently, Citigroup's Jonathan Raviv cited recent wins- especially in transport- as behind his bullish take on the stock.Meanwhile, Drexel Hamilton's David Williams wrote: "We remain positive on CUB and expect further acquisitions to supplement top and bottom-line growth, which is likely to drive short term upside to expectations, and provide a strong long-term growth trajectory."As such, the analyst reiterates his "buy" rating and $85 price target (38% upside potential) on this strong buy stock. Six analysts give the stock a buy rating, while their average price target works out at $76.40. Get the CUB Stock Research Report.TipRanks.com offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at TipRanks.com. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy * 5 Housing Stocks to Buy for Renewed Homebuilder Confidence * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio The post 7 Strong Buy Stocks the Street Loves appeared first on InvestorPlace.
- Kiplinger
5 Biotech Stocks to Buy for Blockbuster Potential
Biotechnology has boomed over the past few decades as our understanding of living organisms and the human machine has swelled. As a result, biotech stocks have become some of the most exciting growth plays on Wall Street.And their potential to deliver sky-high returns is especially explosive when they're developing a drug with blockbuster potential.Blockbuster drugs are those popular treatments that generate annual sales of at least $1 billion. They're uncommon: A drug must have the right combination of price and number of potential patients, so only a handful of treatments at any given time even have the potential to become billion-dollar products. And not all of them live up to their potential.So how can you pinpoint biotech stocks with these kind of superstar drugs in the pipeline? We suggest turning to Wall Street's pros.Here are five promising biotech stocks to buy for their blockbuster-drug potential. TipRanks data shows that all five stocks boast a "Strong Buy" consensus among the Wall Street analysts covering them, based on ratings given during the past three months. SEE ALSO: The 20 Best Small-Cap Dividend Stocks to Buy
- TheStreet.com
Building a Base, Moderna Finds Support at $13.50
Without a lot of price history to work with, the charts show traders can approach the long side of MRNA risking a trade at $13.
- Business Wire
Moderna to Report Second Quarter 2019 Financial Results on Wednesday, August 7th, 2019
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 7, 2019 to report its second quarter 2019 financial results and provide a corporate update. The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for 30 days following the call. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.
- TipRanks
4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts
Investing in biotech stocks can generate substantial returns. If data results meet key targets, or drug applications are accepted, share prices can soar. Unfortunately the reverse is also true. That means investors have to be particularly careful when it comes to biotech stocks. The following four stocks all show a Strong Buy Street consensus- based on ratings received over the last three months. They also boast significant upcoming catalysts this quarter- that could potentially send share prices soaring. Let’s take a closer look at each stock now: 1\. Intercept Pharmaceuticals (ICPT)Intercept Pharma is trying to help patients with progressive non-viral liver diseases. The company already has one drug on the market (for primary biliary cirrhosis), and recently released positive results from the Phase 3 REGENERATE trial in NASH Fibrosis. Nash is a chronic condition in which the buildup of fat and inflammation in the liver may eventually lead to severe scarring called fibrosis. It is currently the second leading cause of liver transplant in the US- making it a very lucrative opportunity for drug companies. Intercept has an early mover advantage here. The company plans to submit an NDA [new drug application] in 3Q19 and an MAA [marketing authorization application] in 4Q19. “Obeticholic Acid will likely be the first to market in NASH and is the only drug to have demonstrated a fibrosis benefit” cheers Needham analyst Alan Carr. “We acknowledge certain potential safety and tolerability limitations, but nevertheless expect the drug to have an important role in NASH therapy over the next several years” says the analyst. Overall the stock has a ‘Strong Buy’ Street consensus, with 5 recent buy ratings vs just 1 hold rating. Meanwhile the average analyst price target of $148 indicates huge upside potential of 113%. >>Click Here to see the full list of ICPT Analyst Ratings 2\. Rhythm Pharmaceuticals (RYTM)Rhythm is developing treatments for rare genetic deficiencies that result in life-threatening metabolic disorders. The big news here is that Rhythm is expected to announce results in 3Q19 from two Phase 3 trials of setmelanotide in POMC and LEPR Deficiency. There are currently no approved drugs for these diseases- and no other drugs in development.“We anticipate a positive outcome for both trials based on Phase 2 data demonstrating a profound and durable impact on appetite and weight” writes Carr. The analyst assumes US approval and launch in 4Q20 (EU 2021) and peak worldwide sales of around $265M in 2032.“Considering recent weakness, we believe the stock is attractive ahead of Phase 3 POMC and LEPR Deficiency trial results. We believe there is even more room for upside for the stock as the company completes label expansion trials in 2020+” enthuses Carr. Most notably label expansion Phase 3 trial in Bardet-Biedl/Alstrom Syndromes remains on track for results in 2H20. Success here adds another $485M in peak sales potential. “Additional patient populations under evaluation in a Phase 2 trial push peak sales above $1B” writes Carr. RYTM has four consecutive recent buy ratings from the Street, with an average price target of $40 (95% upside potential). >>Click Here to see the full list of RYTM Analyst Ratings 3\. Moderna Inc (MRNA)Moderna is hoping to create a new generation of transformative medicines for patients. The company’s approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease. Encouragingly, all seven analysts covering MRNA rate the stock a buy- so no hold or sell ratings here. “We expect Moderna to provide updates on Cytomegalovirus (CMV), Chikungunya, and Methylmalonic Acidemia (MMA) programs by YE19” writes the analyst.While the commercial opportunity in Chikungunya is modest, he believes PK/PD data from the Phase 1 trial will provide valuable insight into the overall predictability of several other mRNA drugs in development at the company.“The stock has fallen substantially from its peak in May 2019. We believe there is an opportunity for upside in 2H19 as the company announces data from the above CMV, Chikungunya, and MMA programs” Carr concludes. Indeed, the Street’s $30 average price target suggests share prices can double in the coming months. >>Click Here to see the full list of MRNA Analyst Ratings 4\. Cara Therapeutics (CARA)Cara Therapeutics has surged 30% in last the three months. In May the company announced positive results from the first of two Phase 3 trials of IV Korsuva in Chronic Kidney Disease (CKD) dialysis patients with pruritus. Pruritus refers to the severe itching of the skin, a common and distressing symptom for patients with chronic kidney disease. Cara Therapeutics CEO Derek Chalmers noted at the time that the company was "particularly encouraged by the early [anti-itching] response with Korsuva injection." Now investors are keeping a close eye on results from the second trial (KALM-2) and from a Phase 2 trial of oral Korsuva in non-dialysis patients with CKD pruritus- both expected in 2H19. “We anticipate a positive outcome for both trials” comments Carr, adding that the recent results point to a favorable outcome for the KALM-2 trial. “We believe the outcome is also a positive indicator for the oral Korsuva programs in CKD pruritus, Liver Disease pruritus, and Atopic Dermatitis, all of which have large commercial opportunities.”Bottom line: “The stock is substantially undervalued.” All six analysts polled are bullish on CARA right now. Meanwhile the average analyst price target stands at $33 (30% upside potential). >>Click Here to see the full list of CARA Analyst RatingsDiscover the latest ratings from top analysts in any sector you choose
- Business Wire
Moderna to Present at ROTH RNA Revolution Conference
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Lorence Kim, M.D., Chief Financial Officer will participate in the ROTH RNA Revolution Conference on July 17, 2019.
- Zacks
Options Traders Expect Huge Moves in Moderna (MRNA) Stock
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
- Insider Monkey
Is Moderna, Inc. (MRNA) A Good Stock To Buy?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- Business Wire
Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Pamela Cohen, M.D., Head, Clinical Oncology Development, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 3:20 p.m. ET. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.
- Simply Wall St.
Moderna, Inc. (NASDAQ:MRNA): Financial Strength Analysis
Stocks with market capitalization between $2B and $10B, such as Moderna, Inc. (NASDAQ:MRNA) with a size of US$5.2b, do...
- Business Wire
Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stephane Bancel, Chief Executive Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019 at 2:00 p.m. PT (5:00 p.m. ET). A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.
- American City Business Journals
MIT gene-therapy spinout raises $6M, enters competitive mRNA field
Strand Therapeutics hopes to create treatments using messenger RNA or mRNA, which gives instructions to the body’s cells to create proteins. But the young gene-therapy startup thinks it has created a better method than such players as Moderna Inc. and Translate Bio.
- Business Wire
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting
Moderna, Inc., (MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced interim data from an ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors. The data showed that the Company’s mRNA personalized cancer vaccine (PCV) mRNA-4157, given alone or in combination with Merck’s pembrolizumab (KEYTRUDA®), was well-tolerated at all doses tested and elicited neoantigen-specific T-cell responses.
- American City Business Journals
Preclinical biotech Stoke Therapeutics plans $86M IPO
An RNA-altering startup led by some of the brains behind Biogen and Sarepta Therapeutics' blockbuster products is hoping to raise $86 million in an IPO, it disclosed Thursday.
- Business Wire
Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle (LNP) can protect from infection by the virus in vivo.
